How much revenue does Lepu Biopharma make?

Lepu Biopharma reported 934.87 million CNY in revenue for fiscal year 2025, up 154.2% from 367.79 million CNY in fiscal year 2024.

Where does Lepu Biopharma make most of its revenue?

People's Republic of China: 61% of revenue by region in fiscal year 2025, followed by Overseas (39%).

What companies are similar to Lepu Biopharma?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include HBM Holdings Limited (2142.HK), CStone Pharmaceuticals (2616.HK), Alphamab Oncology (9966.HK), Jacobio-b (1167.HK).

Lepu Biopharma Co., Ltd. (2157.HK) Stock

About Lepu Biopharma Co., Ltd.

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma. It is also...

At a glance

Lepu Biopharma reported revenue of 934.87 million CNY for fiscal year 2025, up 154.2% from fiscal year 2024, and net income of 261.36 million CNY. People's Republic of China was its largest region in fiscal year 2025, with 61% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.